BCL2L1 and non-Hodgkin lymphoma: Several potent MCL1-specific inhibitors are currently being scrutinized in clinical trials for the treatment of MM and NHL, and selective BCLxL inhibitors have been designed showing significant anti-tumor activity both in vitro and in vivo.